News

Multikine is CEL-SCI’s immunotherapy which was developed as a standard of care in treating head and neck cancer. The Phase III trial is designed to determine if Multikine

BioSante Pharma said that LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD). The efficacy

Zalicus said that the US patent no. 7,915,265 entitled ‘Combinations for the Treatment of Immunoinflammatory Disorders’ offers coverage for Synavive through August 2025. Synavive is indicated for the

MicroCHIPS claims that the current patent in combination with US patent no. 7,070,590 offers coverage for the design and fabrication of reservoir-based medical devices used for implantable drug

Valeant is planning to commence a consent solicitation process during the week of April 4th in an effort to replace Cephalon’s current Board of Directors with its own

The Health Sciences Clinical Development Center 3.1 provides integration, increased automation, and expanded data standardization to enable accelerated processing of clinical trial data from multiple sources in a

As per the terms of the agreement, Minophagen is expected to get license for the development and commercialization of Eisai‘s Bexarotene in Japan. However, Eisai is expected to

The double blind, placebo controlled, multi-center clinical study will evaluate the effects of OCA compared with placebo in adult NASH patients. The 72-week study will enroll 280 patients

As per the terms of the agreement, Shionogi is responsible to pay technology access fees and payments to Shionogi for follow-up chemistry for the generation of various, novel